Clinical Trials
3 trialsNCT05367440 2026-06-01
PETRANHA
AstraZeneca
Phase 1/2 Active not recruiting
NCT01171898 2026-05-11
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT07002320 2026-04-15
ASpiRE
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting